Clinical Trials at Yale Cancer Center
As of September 2026, 67 paid clinical trials are recruiting at Yale Cancer Center, located at 333 CEDAR STREET, DEPARTMENT OF PEDIATRICS , 2073 LMP, NEW HAVEN, CT 06520-8064, phone (203) 785-4640 in New Haven, Connecticut. Active studies at this site cover conditions such as Advanced Solid Tumor, Breast Cancer and Alcohol Use Disorder. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
View the full facility profile →
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
67 clinical trials at Yale Cancer Center
·Clear filters·A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
A Study of PHST001 in Advanced Solid Tumors
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
XTX301 in Patients With Advanced Solid Tumors
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
QTX3034 in Patients With KRAS G12D Mutation
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors
A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
A Clinical Study of YL205 in Patients With Advanced Solid Tumors
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
Common conditions studied in New Haven
- Advanced Solid Tumor (22 active studies)
- Breast Cancer (20 active studies)
- Alcohol Use Disorder (16 active studies)
- Acute Myeloid Leukemia (13 active studies)
- Advanced Solid Tumors (12 active studies)
- Heart Failure (11 active studies)
Leading research sponsors in New Haven
- Yale University
- National Cancer Institute (NCI)
- Children's Oncology Group
- SWOG Cancer Research Network
- Merck Sharp & Dohme LLC
Frequently asked questions
How many paid clinical trials are currently recruiting in New Haven?
There are approximately 850 recruiting clinical trials in New Haven, Connecticut listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in New Haven pay participants?
Most recruiting trials in New Haven compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in New Haven?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in New Haven?
The most common conditions under active study in New Haven include Advanced Solid Tumor (22), Breast Cancer (20), Alcohol Use Disorder (16), Acute Myeloid Leukemia (13), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in New Haven?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in New Haven on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in New Haven?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in New Haven?
Recruiting research sites in New Haven include Yale University, Yale Cancer Center, Yale New Haven Hospital, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in New Haven right now?
The largest active categories in New Haven are Cancer & tumors (312), Neurology & pain (46), Cardiovascular (39). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of Yale Cancer Center?
Yale Cancer Center is located at 333 CEDAR STREET, DEPARTMENT OF PEDIATRICS , 2073 LMP, NEW HAVEN, CT 06520-8064. Use the Google Maps link in the intro above to get directions.
How do I contact Yale Cancer Center?
You can reach Yale Cancer Center by phone at (203) 785-4640. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.